RTOG Foundation Study 3503

Status Date:  October 15, 2019  | Status:  Completed

Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

Principal Investigator

Manmeet Ahluwalia, MD

Primary Objective

To determine the efficacy of TTFields Therapy with bevacizumab as measured by the overall survival rate at 6 months from the time of registration.

Patient Population

Confirmation of recurrence or progression on contract MRI of histologically proven GBM or other grade IV malignant glioma.

Participating Sites

Institution Name City State/Country
Emory University, Winship Cancer Institute Atlanta GA
Froedert and Medical College of Wisconsin Menomonee Falls WI
Medical University of South Carolina Charleston SC
University of California San Diego Moores Cancer Center La Jolla CA
University of Florida Health Cancer Center Orlando FL
University of California Irvine, Chao Family Comprehensive Cancer Center Orange CA
University of Rochester Rochester NY
Washington University School of Medicine St. Louis MO

Participate in RTOG Research

To participate as an RTOG study investigator, your organization must be part of the RTOG Foundation network. Patients who wish to participate in a study must be under the care of an RTOG participating investigator. For additional information, email info@rtog.org or call 1-215-574-3173.

See our clinical trials